MedTrace Logo

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

NCT05172596 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2026-01-13

No results posted yet for this study

Summary

This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma

Conditions

Interventions

BIOLOGICAL

PHE885

Intravenous (IV) infusion

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-03
Primary Completion
2025-05-21
Completion
2025-05-21
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • Canada
  • France
  • Germany
  • Greece
  • Israel
  • Italy
  • Japan
  • Saudi Arabia
  • Singapore
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05172596 on ClinicalTrials.gov